Related Experiment Video
Updated: Sep 12, 2025

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Dysregulated Cholesterol Metabolism and Its Impact on the Tumour Immune Response in Colorectal Cancer
Chunyu Zhang1, Zhiwei Miao1, Yan Xu1
1Department of Gastroenterology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, China.
Abstract:
Colorectal cancer (CRC) ranks among the primary causes of cancer deaths worldwide. Cholesterol metabolism, tightly regulated through biosynthesis, uptake, efflux and conversion, plays a crucial role in CRC development and progression. Dysregulated cholesterol metabolism in cancer cells alters the tumour microenvironment (TME), promoting tumour progression and immune escape. Recent studies highlight the relationship between cholesterol metabolism and the body's immune reactions, showing that cholesterol and its metabolites can modulate immune cell function, driving pro-tumorigenic or anti-tumour effects. Targeting cholesterol metabolism has shown promise in enhancing immunotherapy outcomes, such as inhibiting specific enzymes or transporters to improve T cell infiltration and activation. In this review, we provide a comprehensive overview of the functions of cholesterol and its metabolites in the immune response and the latest advances in CRC therapy targeting cholesterol metabolism.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Cholesterol: Significance and Regulation
Considering cholesterol and...
Tumor Immunotherapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

